| US 7,476,666 B2 | ||
| HIV integrase inhibitors | ||
| John S. Wai, Harleysville, Pa. (US); Peter D. Williams, Harleysville, Pa. (US); and H. Marie Langford, Lansdale, Pa. (US) | ||
| Assigned to Merck & Co., Inc., Rahway, N.J. (US) | ||
| Appl. No. 11/629,153 PCT Filed Jun. 03, 2005, PCT No. PCT/US2005/022807 § 371(c)(1), (2), (4) Date Dec. 08, 2006, PCT Pub. No. WO2005/120516, PCT Pub. Date Dec. 22, 2005. |
||
| Claims priority of provisional application 60/578170, filed on Jun. 09, 2004. | ||
| Prior Publication US 2008/0015187 A1, Jan. 17, 2008 | ||
| Int. Cl. C07D 487/04 (2006.01); C07D 413/06 (2006.01); C07D 471/04 (2006.01); A61K 31/55 (2006.01); A61K 31/535 (2006.01); A61K 31/495 (2006.01); A61P 31/18 (2006.01) | ||
| U.S. Cl. 514—221 [514/233.2; 514/250; 540/502; 544/117; 544/346; 544/350] | 11 Claims |
1. A compound of Formula I, or a pharmaceutically acceptable salt thereof:
![]() Z is O or N(R8);
R1 and R2 are each independently
(1) H,
(2) C1-6 alkyl,
(3) C1-6 haloalkyl,
(4) C1-6 alkyl substituted with —OH, —O—C1-6 alkyl, —O—C1-6 haloalkyl, —CN, —NO2, —N(RC)RD, —C(O)N(RC)RD, —C(O)RA, —CO2RA, —SRA, —S(O)RA, —SO2RA, —SO2N(RC)RD, —N(RA)C(O)RB, —N(RA)CO2RB, —N(RA)SO2RB, —N(RA)SO2N(RC)RD, —OC(O)N(RC)RD, —N(RA)C(O)N(RC)RD, or —N(RA)C(O)C(O)N(RC)RD,
(5) CycA,
(6) AryA,
(7) HetA, or
(8) C1-6 alkyl substituted with CycA, AryA, or HetA;
R3, R4, R5 and R6 are defined as follows:
(A) R3, R4, R5 and R6 are each independently:
(1) H,
(2) C1-6 alkyl,
(3) C1-6 haloalkyl,
(4) C1-6 alkyl substituted with —OH, —O—C1-6 alkyl, —O—C1-6 haloalkyl, —CN, —NO2, —N(RC)RD, —C(O)N(RC)RD, —C(O)RA, —CO2RA, —SRA, —S(O)RA, —SO2RA, —SO2N(RC)RD, —N(RA)C(O)RB, —N(RA)CO2RB, —N(RA)SO2RB, —N(RA)SO2N(RC)RD, —OC(O)N(RC)RD, —N(RA)C(O)N(RC)RD, or —N(RA)C(O)C(O)N(RC)RD,
(5) C(O)N(RC)RD,
(6) CycA,
(7) AryA,
(8) HetA, or
(9) C1-6 alkyl substituted with CycA, AryA, or HetA; or
(B) R4 and R5 are each independently defined as in Part (A) above; and R3 and R6 together form a direct bond resulting in a carbon-carbon double bond; or
(C) R4 and R5 together with the carbon atoms to which they are attached form a 5- to 7-membered saturated or unsaturated ring optionally
containing 1 or 2 heteroatoms independently selected from N, O and S, wherein the ring is optionally substituted with from
1 to 6 substituents each of which is independently halogen, —C1-6 alkyl, —OH, —O—C1-6 alkyl, oxo, —CN, —NO2, or —N(RA)RB; and R3 and R6 are either both absent or are each independently defined as in Part (A) above;
R7 is:
(1) OH,
(2) O—C1-6 alkyl,
(3) O-CycA,
(4) O—C1-6 alkylene-CycA,
(5) O—C1-6 alkylene-AryA,
(6) O—C1-6 alkylene-HetA, or
(7) N(RU)RV;
R8 is:
(1) H,
(2) C1-6 alkyl,
(3) C1-6 haloalkyl,
(4) C1-6 alkyl substituted with —OH, —O—C1-6 alkyl, —O—C1-6 haloalkyl, —CN, —NO2, —N(RC)RD, —C(O)N(RC)RD, —C(O)RA, —CO2RA, —SRA, —S(O)RA, —SO2RA, —SO2N(RC)RD, —N(RA)C(O)RB, —N(RA)CO2RB, —N(RA)SO2RB, —N(RA)SO2N(RC)RD, —OC(O)N(RC)RD, —N(RA)C(O)N(RC)RD, or —N(RA)C(O)C(O)N(RC)RD,
(5) CycA, or
(6) C1-6 alkyl substituted with CycA, AryA, or HetA;
n is an integer equal to zero or 1;
each RA is independently —H or —C1-6 alkyl;
each RB is independently —H or —C1-6 alkyl;
RC and RD are each independently —H or —C1-6 alkyl; or RC and RD together with the N atom to which they are both attached form a 3- to 8-membered saturated ring containing (i) the N atom
to which they are both attached, (ii) at least two carbon atoms, and (iii) optionally 1 or 2 additional heteroatoms independently
selected from N, O and S; wherein the ring is optionally substituted with from 1 to 6 substituents each of which is independently
halogen, —C1-6 alkyl, —OH, —O—C1-6 alkyl, oxo, —CN, —NO2, or —N(RA)RB;
RU and RV are each independently:
(i) H,
(ii) C1-6 alkyl,
(iii) C1-6 haloalkyl,
(iv) C1-6 alkyl substituted with —OH, —O—C1-6 alkyl, —O—C1-6 haloalkyl, —CN, —NO2, —N(RC)RD, —C(O)N(RC)RD, —C(O)RA, —CO2RA, —SRA, —S(O)RA, —SO2RA, —SO2N(RC)RD, —N(RA)C(O)RB, —N(RA)CO2RB, —N(RA)SO2RB, —N(RA)SO2N(RC)RD, —OC(O)N(RC)RD, —N(RA)C(O)N(RC)RD, or —N(RA)C(O)C(O)N(RC)RD,
(v) CycA,
(vi) HetC, or
(vii) C1-6 alkyl substituted with CycA, AryA, HetA, or HetC, with the proviso that the atom in HetC attached to the alkyl group is not
a N atom; or
RU and RV together with the N atom to which they are both attached form a 3- to 8-membered saturated ring containing (i) the N atom
to which they are both attached, (ii) at least two carbon atoms, and (iii) optionally containing 1 or 2 additional heteroatoms
independently selected from N, O and S; wherein the saturated ring is optionally fused with a benzene ring and the optionally
fused, saturated ring is:
(i) optionally substituted with from 1 to 6 substituents each of which is independently halogen, —C1-6 alkyl, —OH, —O—C1-6 alkyl, oxo, —CN, —NO2, or —N(RA)RB, and
(ii) optionally substituted with 1 or 2 substituents each of which is independently CycA, AryA, HetA, HetC, or C1-6 alkyl substituted with CycA, AryA, HetA or HetC;
each CycA is independently a C3-8 cycloalkyl which is:
(i) optionally substituted with from 1 to 6 substituents each of which is independently halogen, —C1-6 alkyl, —OH, —O—C1-6 alkyl, or —C1-6 haloalkyl, and
(ii) optionally substituted with 1 or 2 substituents each of which is independently:
(1) AryB,
(2) HetB,
(3) CycB, or
(4) C1-6 alkyl substituted with CycB, AryB, or HetB;
each AryA is independently an aryl which is:
(i) optionally substituted with from 1 to 5 substituents each of which is independently:
(1) —C1-6 alkyl, which is optionally substituted with —OH, —O—C1-6 alkyl, —O—C1-6 haloalkyl, —CN, —NO2, —N(RA)RB, —C(O)N(RA)RB, —C(O)RA, —CO2RA, —SRA, —S(O)RA, —SO2RA, —SO2N(RA)RB, —N(RA)C(O)RB, —N(RA)CO2RB, —N(RA)SO2RB, —N(RA)SO2N(RA)RB, —OC(O)N(RA)RB, —N(RA)C(O)N(RA)RB, or —N(RA)C(O)C(O)N(RA)RB,
(2) —O—C1-6 alkyl,
(3) —C1-6 haloalkyl,
(4) —O—C1-6 haloalkyl,
(5) —OH,
(6) halogen,
(7) —CN,
(8) —NO2,
(9) —N(RA)RB,
(10) —C(O)N(RA)RB,
(11) —C(O)RA,
(12) —CO2RA,
(13) —SRA,
(14) —S(═O)RA,
(15) —SO2RA,
(16) —SO2N(RA)RB,
(17) —N(RA)SO2RB,
(18) —N(RA)SO2N(RA)RB,
(19) —N(RA)C(O)RB,
(20) —N(RA)C(O)—C(O)N(RA)RB, or
(21) —N(RA)CO2RB, and
(ii) optionally substituted with 1 or 2 substituents each of which is independently:
(1) AryB,
(2) HetB,
(3) CycB,
(4) —C1-6 alkyl substituted with CycB, AryB or HetB,
(5) —C(O)N(RA)-CycB or
(6) —C(O)O-CycB;
each HetA is independently a heteroaryl which is:
(i) optionally substituted with from 1 to 5 substituents each of which is independently halogen, —C1-6 alkyl, —C1-6 haloalkyl, —O—C1-6 alkyl, —O—C1-6 haloalkyl, oxo, or —OH; and
(ii) optionally substituted with 1 or 2 substituents each of which is independently AryB, HetB, CycB, or —C1-6 alkyl substituted with AryB, HetB or CycB;
each AryB is independently phenyl or naphthyl, wherein the phenyl or naphthyl is optionally substituted with from 1 to 5 substituents
each of which is independently any one of the substituents (1) to (21) as defined above in part (i) of the definition of AryA;
each HetB is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected
from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is
independently halogen, —C1-6 alkyl, —C1-6 haloalkyl, —O—C1-6 alkyl, —O—C1-6 haloalkyl, or hydroxy;
each CycB is independently a C3-8 cycloalkyl which is optionally substituted with from 1 to 6 substituents each of which is independently halogen, —C1-6 alkyl, —OH, —O—C1-6 alkyl, or —C1-6 haloalkyl;
HetC is a 4- to 7-membered saturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O
and S, wherein the heterocyclic ring is optionally substituted with from 1 to 6 substituents each of which is independently
halogen, —C1-6 alkyl, —C1-6 haloalkyl, —O—C1-6 alkyl, —O—C1-6 haloalkyl, or oxo;
each aryl is independently (i) phenyl or (ii) a 9- or 10-membered bicyclic, fused carbocylic ring system in which at least
one ring is aromatic; and
each heteroaryl is independently (i) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently
selected from N, O and S, wherein each N is optionally in the form of an oxide, or (ii) a 9- or 10-membered bicyclic, fused
ring system containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein either one or both of the rings
contain one or more of the heteroatoms, at least one ring is aromatic, each N is optionally in the form of an oxide, and each
S in a ring which is not aromatic is optionally S(O) or S(O)2.
|